Evidence map›Paper›PMID 30619250›Full record

Trial reportFrontiers in immunology2018

Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.

K K Vidyavijayan, Narayanaiah Cheedarala, Hemalatha Babu, Lucia K Precilla, Pattabiraman Sathyamurthi, Padmapriyadarsini Chandrasekaran, Kailapuri G Murugavel, Soumya Swaminathan, Srikanth P Tripathy, Luke Elizabeth Hanna

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. HIV-2: still off the radar for India's 90-90-90 targets.The Indian journal of medical research · 2021
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

K K VidyavijayanDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Narayanaiah CheedaralaDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Hemalatha BabuDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Lucia K PrecillaDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Pattabiraman SathyamurthiDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Padmapriyadarsini ChandrasekaranDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Kailapuri G MurugavelDepartment of Infectious Diseases Laboratory, Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.
Soumya SwaminathanDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Srikanth P TripathyDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
Luke Elizabeth HannaDivision of HIV/AIDS, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chennai, India.
National Institute of Research in Tuberculosis · INYR Gaitonde Centre for AIDS Research and Education · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, NeutralizingHIV-1HIV-2HIV AntibodiesAdolescentAdultCross ReactionsFemaleHIV InfectionsHumansIndiaMaleMiddle AgedAntibodies, NeutralizingHIV Antibodiesbroadly cross neutralizing antibodyglycan dependent antibodyHIV-2 infectionhost immunityvaccine

Identifiers

PMID30619250
PMCPMC6304510
OpenAlexW2903770277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.